The pill against COVID-19 from Pfizer reduces the risk of death by 90%
Pfizer has suspended testing of its new drug against COVID-19 due to its high effectiveness. Outside observers recommended not to waste time on bureaucratic procedures and to apply for registration of the drug as soon as possible. It is expected that the drug will be approved for use in emergency cases in the coming weeks.
The pill, which was developed at Pfizer, does not prevent infection with coronavirus and does not heal from it, the company clarifies in order to avoid confusion. It is designed to minimize the likelihood of death of patients, and in this regard is really effective. Studies have shown that if you take the drug no later than 3-5 days after the symptoms of COVID-19 are detected, the risk of complications, hospitalization and death is reduced by 90%.
The drug was named “PAXLOVID” (PAXLOVID). It was created on the basis of special antiviral molecules that began to be developed 20 years ago, after humanity met with SARS. It turned out that the nature of the original SARS-CoV virus and the new SARS-CoV-2 are so similar that scientists managed in a short time to “reprogram” a tool designed to combat the first so that it becomes effective against the second.
Pfizer reported that they are going to launch the release of tablets and continue testing in parallel. And they stressed that the introduction of such a medical product to the market does not cancel the need for vaccinations. As the infectious diseases expert Nahid Bhadelia from Boston University put it: “It’s stupid to refuse a seat belt in a car, even if you are sure that in the event of an accident, doctors will “patch” you with a 90% probability.”